Field of business & strategy
Our R&D focuses on new generation immunotherapies for allergic diseases covering unmet needs. For the induction of tolerance, Tolerogenics S.à.r.l. has developed and patent protected key technologies, which can also be used in combination with established allergen- or autoantigen-specific immunotherapy. The intellectual property provides Freedom-To-Operate and will be used to develop therapeutic products for selected diseases. The technology can also be licensed to partner pharma companies.